http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Rongjun Qu,Xilu Ma,Minghua Wang,Changmei Sun,Xiaomei Sun,Shaoying Sun,Ying Zhang,Ping Yin 한국공업화학회 2014 Journal of Industrial and Engineering Chemistry Vol.20 No.6
A series of low generation dendrimer polyamidoamine grafted silica gels (named SiO2-G1.0, SiO2-G2.0,SiO2-G3.0) were synthesized via the homogeneous route. The new materials were characterized byscanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), thermal analysis,pore and surface area analysis, X-ray diffraction analysis (XRD) and elemental analysis. The adsorptionproperties of the three products for Au3+ were studied by batch methods. The adsorbents prepared viathe homogeneous route showed higher adsorption capacities than those via the heterogeneous route. The maximum adsorption capacities for the three could reach up to 1.48, 2.45, and 2.21 mmol g-1,respectively.
A Fuzzy Cerebellar Model Articulation Controller Based Visual Servo System for Robot
Wei Sun,Cong Wang,Shengnan Liu,Baoqiang Wu,Minghua Ouyang 제어·로봇·시스템학회 2012 International Journal of Control, Automation, and Vol.10 No.2
This paper presents a novel online learning visual servo controller integrating the FCMAC with proportion controller for the control of position of manipulator end-effector. Since the FCMAC has good learning capability and fast learning speed, and can save much computer memory space by fuzzy processing of input space division and memory unit activation, it is used to develop an adaptive control law by learning the relationship between the image feature errors and manipulator input, and the aim of online learning of the FCMAC is to minimize the output of proportion controller. Further-more, the FCMAC has no need for models of robot manipulator and image feature extraction, so that the capability of proposed controller for tasks under uncertain environment can be improved. Finally, the proposed controller is proved to be effective by the experiment, and compared with BP neural net-work.
Influence of Silane-based Impregnation Agent on the Permeability of Concretes
Baoju Liu,Jiali Qin,Minghua Sun 대한토목학회 2019 KSCE JOURNAL OF CIVIL ENGINEERING Vol.23 No.8
Three types of silane-based impregnation agent (short for SIA) are used to treat the concrete surface, and the influence of water/ binder (W/B) ratio, mineral admixtures, curing methods, the type and dosage of SIA on the capillary water absorption and electric flux of concretes is examined. Results show that the penetration depth of SIA increases with the increasing of the W/B ratio and SIA dosage, and is related to the type of SIA. Surface treatment by SIA can reduce capillary water absorption and electric flux of concretes, the W/B ratio and curing methods are no longer the main factor, the increasing of the SIA dosage can further improve the surface protection effect of concrete. Mineral admixtures improve the compactness of concretes, and the combined effects of surface treatment and admixtures can evidently enhance the impermeability of concrete. Different types of SIAs have different mechanisms of action on the surface treatment of concrete, and thus have different impacts on the permeability of concrete. The concrete treated by SIA2 with the effects of the penetration and the formation of surface film layer has lower permeability.
Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014)
Lee, Yoonji,Hong, Sunhye,Cui, Minghua,Sharma, Pankaz K,Lee, Jeewoo,Choi, Sun Informa UK, Ltd. 2015 Expert opinion on therapeutic patents Vol.25 No.3
<P>Introduction: Transient receptor potential vanilloid type 1 (TRPV1) is a nonselective cation channel that can be activated by noxious heat, low pH and vanilloid compounds such as capsaicin. Since TRPV1 acts as an integrator of painful stimuli, TRPV1 antagonists can be used as promising therapeutics for new types of analgesics. Areas covered: This review article covers the patents that claim TRPV1 antagonists and were published during 2011 - 2014. The patent evaluation is organized according to the applicant companies, and the representative chemical entities with important in vitro and in vivo data are summarized. Expert opinion: Many pharmaceutical companies showed promising results in the discovery of potent small molecule TRPV1 antagonists, and recently, a number of small molecule TRPV1 antagonists have been advanced into clinical trials. Unfortunately, several candidate molecules showed critical side effects such as hyperthermia and impaired noxious heat sensation in humans, leading to their withdrawal from clinical trials. Some TRPV1 antagonists patented in recent years (2011 - 2014) overcame these undesirable side effects, making the development of TRPV1 antagonists much more promising.</P>
Hoang, Van-Hai,Tran, Phuong-Thao,Cui, Minghua,Ngo, Van T. H.,Ann, Jihyae,Park, Jongmi,Lee, Jiyoun,Choi, Kwanghyun,Cho, Hanyang,Kim, Hee,Ha, Hee-Jin,Hong, Hyun-Seok,Choi, Sun,Kim, Young-Ho,Lee, Jeewoo American Chemical Society 2017 Journal of medicinal chemistry Vol.60 No.6
<P>Glutaminyl cyclase (QC) has been implicated in the formation of toxic amyloid plaques by generating the N-terminal pyroglutamate of beta-amyloid peptides (pGlu-A beta) and thus may participate in the pathogenesis of Alzheimer's disease (AD). We designed a library of glutamyl cyclase (QC) inhibitors based on the proposed binding mode of the preferred substrate, A beta 3E-42. An in vitro structure-activity relationship study identified several excellent QC inhibitors demonstrating 5- to 40-fold increases in potency compared to a known QC inhibitor. When tested in mouse models of AD, compound 212 significantly reduced the brain concentrations of pyroform A beta and total A beta and restored cognitive functions. This potent A beta-lowering effect was achieved by incorporating an additional binding region into our previously established pharmacophoric model, resulting in strong-interactions with the carboxylate group of Glu327 in the QC binding site. Our study offers useful insights in designing novel QC inhibitors as a potential treatment option for AD.</P>
5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATcl expression
( Ju Hee Kang ),( Zheng Ting ),( Mi Ran Moon ),( Jung Seon Sim ),( Jung Min Lee ),( Kyung Eun Doh ),( Sunhye Hong ),( Minghua Cui ),( Sun Choi ),( Hyeun Wook Chang ),( Hea Young Park Choo ),( Mijung Y 영남대학교 약품개발연구소 2016 영남대학교 약품개발연구소 연구업적집 Vol.26 No.-
5-Lipoxygenase synthesizes leukotrienes from arachidonic acid. We developed three novel 5-LO inhibi-tors having a benzoxazole scaffold as a potential anti-osteoclastogenics. They significantly suppressed RANKL-induced osteoclast formation in mouse bone marrow-derived macrophages. Furthermore, one compound. K7, inhibited the bone resorptive activity of osteoclasts. The anti-osteoclastogenic effect of K7 was mainly attributable to reduction in the expression of NFATc1. an essential transcription factor for osteoclast differentiation. K7 inhibited osteoclast formation via ERK and p38 MAPK. as well as NF-KB signaling pathways. K7 reduced lipopolysaccharide (LPS)-induced osteoclast formation in vivo. corroborating the in vitro data. Thus, IG exerted an inhibitory effect on osteoclast formation in vitro and in vivo, properties that make it a potential candidate for the treatment of bone diseases associated with excessive bone resorption.
Ngo, Van T.H.,Hoang, Van-Hai,Tran, Phuong-Thao,Ann, Jihyae,Cui, Minghua,Park, Gyungseo,Choi, Sun,Lee, Jiyoun,Kim, Hee,Ha, Hee-Jin,Choi, Kwanghyun,Kim, Young-Ho,Lee, Jeewoo Elsevier 2018 Bioorganic & medicinal chemistry Vol.26 No.5
<P><B>Abstract</B></P> <P>Pyroglutamate-modified amyloid β peptides (pGlu-Aβ) are highly neurotoxic and promote the formation of amyloid plaques. The pGlu-Aβ peptides are generated by glutaminyl cyclase (QC), and recent clinical studies indicate that QC represents an alternative therapeutic target to treat Alzheimer’s disease (AD). We have previously developed a series of QC inhibitors with an extended pharmacophoric scaffold, termed the Arg-mimetic D-region. In the present study, we focused on the structure activity relationship (SAR) of analogues with modifications in the D-region and evaluated their biological activity. Most compounds in this series exhibited potent activity in vitro, and our SAR analysis and the molecular docking studies identified compound <B>202</B> as a potential candidate because it forms an additional hydrophobic interaction in the <I>h</I>QC active site. Overall, our study provides valuable insights into the Arg-mimetic pharmacophore that will guide the design of novel QC inhibitors as potential treatments for AD.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Ngo, Van T.H.,Hoang, Van-Hai,Tran, Phuong-Thao,Van Manh, Nguyen,Ann, Jihyae,Kim, Eunhye,Cui, Minghua,Choi, Sun,Lee, Jiyoun,Kim, Hee,Ha, Hee-Jin,Choi, Kwanghyun,Kim, Young-Ho,Lee, Jeewoo Elsevier 2018 Bioorganic & medicinal chemistry Vol.26 No.12
<P><B>Abstract</B></P> <P>Glutamyl cyclase (QC) is a promising therapeutic target because of its involvement in the pathogenesis of Alzheimer’s disease. In this study, we developed novel QC inhibitors that contain 3-aminoalkyloxy-4-methoxyphenyl and 4-aminoalkyloxyphenyl groups to replace the previously developed pharmacophore. Several potent inhibitors were identified, showing IC<SUB>50</SUB> values in a low nanomolar range, and were further studied for <I>in vitro</I> toxicity and <I>in vivo</I> activity. Among these, inhibitors <B>51</B> and <B>53</B> displayed the most potent Aβ<SUB>N3pE−40</SUB>-lowering effects in <I>in vivo</I> acute model with reasonable BBB penetration, without showing cytotoxicity and <I>h</I>ERG inhibition. The molecular modeling analysis of <B>53</B> indicated that the salt bridge interaction and the hydrogen bonding in the active site provided a high potency. Given the potent activity and favorable BBB penetration with low cytotoxicity, we believe that compound <B>53</B> may serve as a potential candidate for anti-Alzheimer’s agents.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Inhibitory effect of tartrate against phosphate-induced DJ-1 aggregation
Kim, Min Soo,Lee, Sangmin,Yun, Sanguk,Suh, Pann-Ghill,Park, Jongmi,Cui, Minghua,Choi, Sun,Cha, Sun-Shin,Jin, Wook Elsevier 2018 INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES Vol.107 No.2
<P><B>Abstract</B></P> <P>The DJ-1 protein engages in diverse cellular and pathological processes, including tumorigenesis, apoptosis, sperm fertilization, and the progression of Parkinson’s disease (PD). The functional dimeric form of DJ-1 transforms into non-functional filamentous aggregates in an inorganic phosphate (P<SUB>i</SUB>)-dependent manner in vitro. Here, we demonstrated that P<SUB>i</SUB> and reactive oxygen species (ROS) induce DJ-1 aggregation in Neuro2A and SH-SY5Y cells. Remarkably, tartrate treatment significantly reduced P<SUB>i</SUB>- and ROS-induced DJ-1 aggregation and restored P<SUB>i</SUB>- and ROS-provoked cell death using quantitative data as mean±standard deviation, and statistics. Mechanistically, tartrate prevented DJ-1 aggregation via occupying the P<SUB>i</SUB>-binding site. These findings revealed an unexpected physiological role of tartrate in the maintenance of DJ-1 function, and thus, a potential use as an inhibitor of DJ-1 aggregation.</P>